The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,317,036 | -3,612,231 |
| Depreciation | 12,225 | 15,930 |
| Amortization | 10,605 | 20,545 |
| Amortization of rou asset | 0 | 0 |
| Amortization of capitalized share-based payments | 44,118 | 88,235 |
| Share-based compensation under equity incentive plan | 34,882 | 177,148 |
| Change in fair value of derivative liabilities | -21,103 | -135,342 |
| Write-offs of capitalized patents | 0 | 0 |
| Change in inventory reserve | 244,682 | - |
| Accounts receivable | 379,002 | -191,714 |
| Prepaid and other assets | 253,538 | -263,911 |
| Inventory | -27,735 | 356,657 |
| Accounts payable and accrued liabilities | 445,639 | 9,739 |
| Accrued interest, net | 485 | -18,830 |
| Reduction of lease liability | 0 | 0 |
| Net cash used in operating activities | -2,109,072 | -3,047,494 |
| Capitalization of patents | 13,703 | 7,165 |
| Purchases of fixed assets | 9,999 | 50,001 |
| Acquisition of intangibles | 1,785 | 0 |
| Purchase of short-term investments | 0 | - |
| Maturities of short-term investments | 0 | 1,708,000 |
| Net cash provided by (used in) investing activities | -25,487 | 1,650,834 |
| Net proceeds from january 2024 offering | 0 | 0 |
| Net proceeds from january 2025 offering | 0 | 804,346 |
| Net proceeds from february 2025 offering | 0 | 908,627 |
| Net proceeds from july 2025 offering | 4,281,300 | - |
| Shares withheld for net share settlement of performance bonuses | 0 | 18,000 |
| Net proceeds from atm offering | 0 | - |
| Payment of deferred offering costs for proposed offering | - | 0 |
| Net proceeds from private placement | 0 | - |
| Proceeds from exercise of pre-funded warrants | 878 | 1,926 |
| Net cash provided by financing activities | 4,282,178 | 1,696,899 |
| Effect of exchange rate changes on cash | 1,230 | 7,338 |
| Change in cash and cash equivalents | 2,148,849 | 307,577 |
| Cash and cash equivalents at beginning of period | 1,659,353 | - |
| Cash and cash equivalents at end of period | 4,115,779 | - |
60 DEGREES PHARMACEUTICALS, INC. (SXTPW)
60 DEGREES PHARMACEUTICALS, INC. (SXTPW)